SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-22-004626
Filing Date
2022-03-02
Accepted
2022-03-02 07:37:16
Documents
14
Period of Report
2022-03-02
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K avtx-20220302.htm   iXBRL 8-K 35347
2 EX-99.1 ex-991earningsrelease4q2021.htm EX-99.1 108647
6 GRAPHIC avalologoa.jpg GRAPHIC 8535
  Complete submission text file 0001628280-22-004626.txt   300686

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT avtx-20220302.xsd EX-101.SCH 1967
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT avtx-20220302_lab.xml EX-101.LAB 23180
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT avtx-20220302_pre.xml EX-101.PRE 12039
8 EXTRACTED XBRL INSTANCE DOCUMENT avtx-20220302_htm.xml XML 10011
Mailing Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850
Business Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850 410-522-8707
Avalo Therapeutics, Inc. (Filer) CIK: 0001534120 (see all company filings)

IRS No.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37590 | Film No.: 22701365
SIC: 2834 Pharmaceutical Preparations